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Background: Eisenmenger syndrome (ES) in the adult population has become exceedingly rare in devel-
oped countries owing to better recognition and treatment of congenital malformations of the heart. In
the absence of transplantation, most patients survive an average of 20–30 years before succumbing to
the cardiovascular and hemostatic sequelae. We present a rare case of an elderly woman with ES sec-
ondary to an uncorrected atrial-septum defect. She continues to have a high functional capacity despite
impressive hemodynamic parameters.
Case: A 69-year-old woman with ES presented to our facility with atrial ﬁbrillation and volume overload.
She has a known sinus venosus atrial septal defect and associated severe pulmonary hypertension. She
was managed conservatively and discharged on bosentan given her intricate physiology.
Conclusion: Given the similarity of the pathology with idiopathic pulmonary arterial hypertension (IPAH)
and ES, drugs that are usually reserved for IPAH such as prostanoids and phosphodiesterase type 5
inhibitors may be beneﬁcial in the management of ES. This case highlights that with our improving
understandingof ES, non-operativemanagementmayhaveanexpanding role in the careof these complex
patients.
<Learningobjective: Advanced therapy for Eisenmenger syndrome (ES) is geared toward theendothelin-
1 mediated pulmonary arterial plexus. Given the similarity of the pathology with idiopathic pulmonary
arterial hypertension (IPAH) and ES, drugs that are usually reserved for IPAH such as prostanoids and
phosphodiesterase type 5 inhibitors may be beneﬁcial in the management of ES. Conservative manage-
ment can achieve a favorable outcome, even in elderly patients with advanced disease.>
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Eisenmenger syndrome (ES) in the adult population has become
are in developed countries owing to better recognition and treat-
ent of congenital malformations of the heart [1]. This syndrome
s driven by the physiologic consequence of unchecked systemic-
o-pulmonary shunting resulting in right-sided heart overload and
ncreased pulmonary vascular resistance. Eventual reversal of this
hunt manifests as pulmonary hypertension, cyanosis, hypoxia,
ongestive heart failure, and erythrocytosis among other issues
2]. In the absence of transplantation (combined heart/lung or lung
ith correction of the underlying defect), most patients survive
n average of 20–30 years before succumbing to the cardiovas-
ular and hemostatic sequelae. Medical management is centered
round obviating complications and improving symptoms, strate-
ies that have had disappointing results on patient mortality; in
ne series, untransplanted patients had an average age of death
f 37 [3]. We present a rare case of an elderly woman with ES
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secondary toanuncorrectedatrial-septumdefect. Aswill be shown,
she continues to have a high functional capacity despite impres-
sive hemodynamic parameters. This case highlights that with our
improving understanding of ES, non-operative management may
have an expanding role in the care of these complex patients.
Case report
Our patient is a 69-year-oldwomanwith a history of pulmonary
hypertension secondary to ES. She originally presented to her pri-
mary care provider in 1999 with a 2-year history of progressive
dyspnea on exertion. The patient was evaluated and discovered
to have evidence of a sinus venosus atrial septal defect (ASD),
severe pulmonary hypertension, and secondary polycythemia. She
was referred to our facility at that time and underwent a car-
diac catheterization that revealed elevated right-sided pressures
[right atrium(RA): 3; right ventricle (RV): 98/14mmHg;pulmonary
artery (PA): 108/45mmHg; mean 69mmHg] (Table 1). A Hickman
catheter was placed and she was started on epoprostenol.
In 2003, a catheterization was performed to assess her for
transplant necessity. At that time, her mean PA pressure was
72mmHg, RA 10mmHg, RV end-diastolic 10mmHg, and saturation
ollege of Cardiology.
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Table 1
Right sided heart catheterization values.
Cardiac
catheterization
(1999)
Cardiac
catheterization
(2003)
Cardiac
catheterization
(2007)
Cardiac
catheterization
(2010)
Right atrium 3 10 18 13
Right ventricle 98/14 96/10 120/12 115/10
Pulmonary artery 108/45
Mean 69
114/48
Mean 72
120/58
Mean 78
115/52
Mean 79
A senta
i
r
7
i
m
s
b
t
t
h
1
t
a
w
h
H
i
6
T
a
w
t
o
a
a
F
m
v
Despite her periodic desaturations, the patient was very active and
largely asymptomatic at baseline. Shewas subsequentlydischarged
once she was at her functional baseline.ll units are expressed in mmHg. Epoprostenol was started in 1999. Epoprostenol, bo
n 2010.
un included a femoral artery saturation of 90.8, pulmonary artery
3.8, pulmonary venous 97.9, which reﬂected a marked reduction
n the right-to-left shunt (Table 1). Using the Fick equation, the pul-
onary blood ﬂow was 4.55, systemic ﬂow 4.51, and right-to-left
hunt of 1.02 and left-to-right shunt of 1.06. PVR was calculated to
e 13.6Wood units. The pressure hemodynamics were similar but
he improvement in functional status was quite impressive as was
he forwardﬂowanddecrease in right-to-left shunt. In 2007, repeat
eart catheterization at that timedemonstratedRAof 18mmHg,RV
20–15mmHg, PA 120/58mmHg, and PCW was 27mmHg.
In April 2010, she was gradually improving and was WHO func-
ional class II on epoprostenol, bosentan, spironolactone, warfarin,
nd triamterene. She had been considered for transplant, but this
as deferred because of her clinical stability.
In 2010, we repeated the right heart catheterization because of
er age and concern that shewould no longer be transplant eligible.
er thermodilution cardiac output was 3.25, which probably was
naccurate based on the ASD, and mixed venous saturation was
5.7with arterial saturation 92,whichwas a goodAVO2difference.
he RA pressure was improved to 13mmHg. The wedge pressure
gain was read as in the mid-20s. Her oxygen saturation at rest
as approximately 90–92%; however, she was noted to desaturate
o 70% with minimal exertion (Table 1).
On 4/2012, the patient was transported to our facility from an
utside hospital (OSH) due to dyspnea, increased abdominal girth,
nd a 4.5 kg weight gain over two days. Initial evaluation included
chest X-ray and transthoracic echocardiogram (Figs. 1 and 2,
ig. 1. Anteroposterior chest roentgenogram demonstrating enlarged cardiopul-
onary silhouette, dilated right cardiac chambers, andcongested central pulmonary
asculature consistent with severe pulmonary hypertension.n, spironolactone, and triamterene were started prior to the cardiac catheterization
respectively). In the OSH, she was saturating in the 70s on room
air and was tachycardic with a heart rate in the 170s; she was in
atrial ﬂutter. Shewas startedondiltiazemandbecamehypotensive.
She was cardioverted once with no change in rhythm. The patient
was intubated due to persistent hypoxia and hypotension. She was
airlifted to our facility.
Diuresis was started given evidence of volume overload. An
amiodarone drip was started given her atrial ﬂutter. She was
extubated shortly thereafter and returned to her baseline oxygen
saturation (approximately 90%) while on 4 L NC. Her amiodarone
drip was discontinued and she was transitioned to metoprolol; she
maintained sinus rhythm and was transferred out of the intensive
care unit. The patient’s metoprolol was further titrated and she
was carefully diuresed while on the ward; her oxygen requirement
decreased till supplemental oxygen was discontinued altogether.Fig. 2. Transthoracic echocardiograms. (A) Four chamber viewdemonstrating small
and compressed left ventricle (LV) due to intraventricular septal wall motion,
severelydilated right atrium(RA)andrightventricle (RV). LA, left atrium. (B)Doppler
enhanced imaging showing severe tricuspid regurgitant jet as well preserved left
ventricular ejection fraction (estimated at 75%).
e ardiol
D
n
a
s
d
r
h
d
p
a
y
t
u
a
s
s
p
l
o
p
a
d
o
l
[
[
[
[
[116 Y. Rodriguez et al. / Journal of C
iscussion
This case highlights several key clinical factors regarding the
atural course and management of patients with ES, speciﬁcally in
ssociation with sinus venosus ASD. Because of the availability of
urgical or percutaneous correction of congenital heart defects, the
evelopmentof a reversal of shuntﬂowtoa right-to-left direction is
elatively uncommon. Accordingly, moderate to severe pulmonary
ypertension is present in less than 10% of patients at the time of
iagnosis of an ASD. Of those patients that do ultimately develop
ulmonary hypertension, those with a sinus venosus defect with
nomalous pulmonary venous return are known to do so at a
ounger age compared to other forms of ASD [4]; therefore, the fact
hat she was asymptomatic until she was in her 50s is exceedingly
ncommon.
Advanced therapy for ES geared toward the endothelin-1 medi-
ted pulmonary arterial plexus vasoconstriction of ES has been
tudied. The Breathe-5 trial, a double-blind, placebo-controlled
tudy, concluded that the use of bosentan compared to placebo in
atients with ES is associated with a decrease in pulmonary vascu-
ar resistance index without compromising systemic arterial blood
xygenation [5]. Given the similarity of the pathology with idio-
athic pulmonary arterial hypertension (IPAH) and ES, drugs that
re usually reserved for IPAH such as prostanoids and phospho-
iesterase type 5 inhibitors may be beneﬁcial in the management
f ES [6]. The physiology associated with ES lends itself to base-
ine arterial oxygenation statistics that clinicians rarely encounter
[ogy Cases 7 (2013) e114–e116
among patients outside of an ICU setting. This case illustrates an
atypical presentation of the clinical manifestations of a congenital
heart defect, andhowmedicalmanagement can achieve a favorable
clinical outcome.
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